



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

**Public Declaration of Interests and Confidentiality Undertaking of  
European Medicines Agency (EMA),  
Scientific Committee members and experts**

**Public declaration of interests**

**I, Ana Opinião**

**Organisation/Company:** National Authority of Medicines and Health Products, I.P.

**Country:** Portugal

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

No interest declared

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

No interest declared

2.6 Investigator

Period	Company	Products	Therapeutic Indication
11/2007-04/2012	SanofiAventis	Aflibercept	Metastatic prostate cancer

06/2008-07/2010	AstraZeneca	AZD0530	Advanced Ovarian Cancer
07/2010-12/2016	Boehringer Inelheim	BIBF 1120	Advanced Ovarian Cancer
09/2009-07/2013	Eisai Ltd	Farletuzumab	Advanced Ovarian Cancer

## 2.7 Grant / Funding to organisation /institution

No interest declared

## 2.8 Close family member interest

No interest declared

## 2.9 Any other interests or facts

Although I'm not directly involved, I work in an institution where some physicians provide consultancy advice for pharmaceutical companies (mostly in the form of advisory boards).  
I have participated in an educational activity for elements from the pharmaceutical industry (AstraZeneca), organized by my institution, on the theme "Ovarian Cancer" (January 2016).  
I have participated, as co-investigator, in one academic trial involving pharmaceutical products: the BRCA Trial, a randomized phase II pilot trial of Carboplatin compared to Docetaxel for patients with metastatic genetic breast cancer (from the Breakthrough Breast Cancer & Cancer Research UK) - from October 2008 to June 2013.

## CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

**"EMA Activities"** encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

**"Confidential Information"** means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

**"Confidential Documents"** mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

<b>Full Name:</b>	Ana Sofia Gaspar Opinião
<b>Date:</b>	2020-04-14

*For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template*